Business Description
IRLAB Therapeutics AB
ISIN : SE0012675361
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 4.04 | |||||
Equity-to-Asset | 0.65 | |||||
Debt-to-Equity | 0.24 | |||||
Debt-to-EBITDA | -0.16 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -0.62 | |||||
Beneish M-Score | 1.24 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -21.3 | |||||
3-Year EPS without NRI Growth Rate | -21.3 | |||||
3-Year FCF Growth Rate | -19.2 | |||||
3-Year Book Growth Rate | -32.2 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 69.81 | |||||
9-Day RSI | 58.59 | |||||
14-Day RSI | 52.6 | |||||
6-1 Month Momentum % | 104.07 | |||||
12-1 Month Momentum % | 50.56 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.36 | |||||
Quick Ratio | 3.36 | |||||
Cash Ratio | 3.03 | |||||
Days Sales Outstanding | 955.97 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.3 | |||||
Shareholder Yield % | -0.55 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -3183.66 | |||||
Net Margin % | -3132.07 | |||||
FCF Margin % | -2908.49 | |||||
ROE % | -91.46 | |||||
ROA % | -74.41 | |||||
ROIC % | -203.61 | |||||
ROC (Joel Greenblatt) % | -2683.64 | |||||
ROCE % | -89 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 119.72 | |||||
PB Ratio | 5.85 | |||||
Price-to-Tangible-Book | 9.81 | |||||
EV-to-EBIT | -3.55 | |||||
EV-to-EBITDA | -3.64 | |||||
EV-to-Forward-EBITDA | -3.4 | |||||
EV-to-Revenue | 111.19 | |||||
EV-to-Forward-Revenue | 4481.78 | |||||
EV-to-FCF | -3.82 | |||||
Price-to-Net-Current-Asset-Value | 10.88 | |||||
Price-to-Net-Cash | 13.59 | |||||
Earnings Yield (Greenblatt) % | -28.17 | |||||
FCF Yield % | -24.4 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
IRLAB Therapeutics AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil kr) | 5.678 | ||
EPS (TTM) (kr) | -3.44 | ||
Beta | 0 | ||
Volatility % | 116.15 | ||
14-Day RSI | 52.6 | ||
14-Day ATR (kr) | 1.286374 | ||
20-Day SMA (kr) | 11.925 | ||
12-1 Month Momentum % | 50.56 | ||
52-Week Range (kr) | 5.58 - 20.2 | ||
Shares Outstanding (Mil) | 51.87 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
IRLAB Therapeutics AB Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
IRLAB Therapeutics AB Stock Events
Event | Date | Price(kr) | ||
---|---|---|---|---|
No Event Data |
IRLAB Therapeutics AB Frequently Asked Questions
What is IRLAB Therapeutics AB(OSTO:IRLAB A)'s stock price today?
When is next earnings date of IRLAB Therapeutics AB(OSTO:IRLAB A)?
Does IRLAB Therapeutics AB(OSTO:IRLAB A) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |